Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

BACKGROUND: To date, the cornerstone of treatment in patients with advanced or metastatic cholangiocarcinoma (CCA) is systemic chemotherapy based on a combination of gemcitabine and a platinum derivative. Other therapeutic approaches including targeted agents and tyrosine kinase inhibitors (TKI) hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Moehler, Markus, Maderer, Annett, Ehrlich, Anne, Foerster, Friedrich, Schad, Arno, Nickolay, Tanja, Ruckes, Christian, Weinmann, Arndt, Sivanathan, Visvakanth, Marquardt, Jens U., Galle, Peter Robert, Woerns, Marcus, Thomaidis, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330479/
https://www.ncbi.nlm.nih.gov/pubmed/30634942
http://dx.doi.org/10.1186/s12885-018-5223-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330479/
https://www.ncbi.nlm.nih.gov/pubmed/30634942
http://dx.doi.org/10.1186/s12885-018-5223-7

Ejemplares similares